The soluble guanylate cyclase stimulator IW‐1973 prevents inflammation and fibrosis in experimental non‐alcoholic steatohepatitis

The soluble guanylate cyclase stimulator IW‐1973 prevents inflammation and fibrosis in... AbbreviationsATGautophagy‐related proteinBATbrown adipose tissueCDAAHcholine‐deficient, l‐amino acid‐defined, high‐fatCOL1A1/COL1A2collagen type I α1/α2FAT/CD36fatty acid translocaseGUCY1A2guanylate cyclase 1 soluble subunit α2HFDhigh‐fat dietHSLhormone‐sensitive lipaseIL‐1raIL‐1 receptor antagonistLC3microtubule‐associated proteins 1A/1B light chain 3MCP‐1monocyte chemotactic protein 1NAFLDnon‐alcoholic fatty liver diseaseNASnon‐alcoholic fatty liver disease activity scoreNASHnon‐alcoholic steatohepatitissGCsoluble GCSREBP‐1csterol response element‐binding protein 1cTAGstriglyceridesUCP1uncoupling protein 1VASPvasodilator‐stimulated phosphoproteinWATwhite adipose tissueα‐SMAα‐smooth muscle actinIntroductionNon‐alcoholic fatty liver disease (NAFLD) is a multifaceted condition that includes pathological manifestations ranging from the accumulation of neutral lipids in the cytoplasm of hepatocytes (steatosis) to the combination of steatosis with inflammation, a stage known as non‐alcoholic steatohepatitis (NASH) (Sanyal, ). NASH is the aggressive form of NAFLD and increases the risk for advanced liver disease culminating in hepatic fibrosis, cirrhosis and hepatocarcinoma (Sanyal, ). The mechanisms underlying the progression of NASH have not been completely elucidated, but repeated insults to the liver of these patients lead to inflammatory injury, hepatocyte death and the expansion of extracellular matrix (fibrosis) (Friedman, ). Therefore, pharmacological interventions that protect liver cells from inflammatory injury and fibrosis could be useful as a therapy for NASH.Cyclic nucleotides, such as cGMP, play a major role in cell signalling and tissue homeostasis. Pharmacological modulation of the cGMP pathway is a potential target for therapy in complex http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

The soluble guanylate cyclase stimulator IW‐1973 prevents inflammation and fibrosis in experimental non‐alcoholic steatohepatitis

Loading next page...
1
 
/lp/wiley/the-soluble-guanylate-cyclase-stimulator-iw-1973-prevents-inflammation-CNOVrZkFB5
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 The British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
D.O.I.
10.1111/bph.14137
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsATGautophagy‐related proteinBATbrown adipose tissueCDAAHcholine‐deficient, l‐amino acid‐defined, high‐fatCOL1A1/COL1A2collagen type I α1/α2FAT/CD36fatty acid translocaseGUCY1A2guanylate cyclase 1 soluble subunit α2HFDhigh‐fat dietHSLhormone‐sensitive lipaseIL‐1raIL‐1 receptor antagonistLC3microtubule‐associated proteins 1A/1B light chain 3MCP‐1monocyte chemotactic protein 1NAFLDnon‐alcoholic fatty liver diseaseNASnon‐alcoholic fatty liver disease activity scoreNASHnon‐alcoholic steatohepatitissGCsoluble GCSREBP‐1csterol response element‐binding protein 1cTAGstriglyceridesUCP1uncoupling protein 1VASPvasodilator‐stimulated phosphoproteinWATwhite adipose tissueα‐SMAα‐smooth muscle actinIntroductionNon‐alcoholic fatty liver disease (NAFLD) is a multifaceted condition that includes pathological manifestations ranging from the accumulation of neutral lipids in the cytoplasm of hepatocytes (steatosis) to the combination of steatosis with inflammation, a stage known as non‐alcoholic steatohepatitis (NASH) (Sanyal, ). NASH is the aggressive form of NAFLD and increases the risk for advanced liver disease culminating in hepatic fibrosis, cirrhosis and hepatocarcinoma (Sanyal, ). The mechanisms underlying the progression of NASH have not been completely elucidated, but repeated insults to the liver of these patients lead to inflammatory injury, hepatocyte death and the expansion of extracellular matrix (fibrosis) (Friedman, ). Therefore, pharmacological interventions that protect liver cells from inflammatory injury and fibrosis could be useful as a therapy for NASH.Cyclic nucleotides, such as cGMP, play a major role in cell signalling and tissue homeostasis. Pharmacological modulation of the cGMP pathway is a potential target for therapy in complex

Journal

British Journal of PharmacologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial